GALT cross above 200 day moving average after a lengthy period of consolidation in tightening trading range.
Cup and handle.
Leading drug in a pivotal clinical trial for advanced cirrhosis.
- High insider ownership of shares
- Recent hiring of a renowned liver expert VP from big pharma